Chapter 4

Mechanochemical endovenous ablation of small saphenous vein insufficiency using the ClariVein® device

One-year results of a prospective series

European Journal of Vascular and Endovascular Surgery
2013;45:299-303

Doeke Boersma
Ramon R.J.P. van Eekeren
Deborah A.B. Werson
Rutger I.F. van der Waal
Michel M.P.J. Reijnen
Jean-Paul P.M. de Vries
Abstract

Objective
This study evaluated the feasibility, safety and 1-year results of mechanochemical endovenous ablation (MOCA) of small saphenous vein (SSV) insufficiency.

Design
Prospective cohort study.

Materials and methods
Fifty consecutive patients were treated for primary SSV insufficiency with MOCA using the ClariVein\textsuperscript{®} device and polidocanol. Initial technical success, complications, patient satisfaction and visual analogue scale (VAS) pain score were assessed. Anatomic and clinical success was assessed at 6 weeks and at 1 year.

Results
Initial technical success of MOCA was 100%. At the 6-week assessment, all treated veins were occluded. The 1-year follow-up duplex showed anatomic success in 94% (95% confidence interval, 0.87-1). Venous clinical severity score (VCSS) decreased significantly from 3.0 (interquartile range (IQR) 2-5) before treatment to 1.0 (IQR 1-3, P < 0.001) at 6 weeks and to 1.0 (IQR 1-2, P < 0.001) at 1 year. Median procedural VAS score for pain was 2 (IQR 2-4). No major complications were observed, especially no nerve injury.

Conclusions
MOCA is a safe, feasible and efficacious technique for treatment of SSV insufficiency. One-year follow-up shows a 94% anatomic success rate and no major complications.
Introduction

Varicose veins are a common medical condition with an overall prevalence between 20% and 60%\(^1\). The effect of venous insufficiency on health-related quality of life is substantial and comparable with other chronic diseases such as arthritis, diabetes and cardiovascular disease\(^2\). These problems are mostly associated with insufficiency of great saphenous veins (GSVs). However, insufficiency of the small saphenous vein (SSV) is responsible in 15% of patients with varicose veins\(^3\).

Until the 1990s, high ligation, with or without surgical stripping, was the preferred option for venous insufficiency, although there was no standard in surgical treatment of SSV insufficiency. The introduction of minimally invasive endothermal catheter modalities, including endovenous laser ablation (EVLA) and radiofrequency ablation (RFA), hasrevolutionized the treatment of varicose veins. These have become the preferred techniques, with high success rates\(^4,5\).

Most endovenous ablation techniques are based on heating of the vein wall and, therefore, require the instillation of tumescent anaesthesia. Despite tumescent, thermal-associated complications, such as prolonged pain and skin burn, have been described. The risk of sural nerve injury is a major concern in surgical stripping and endovenous thermal ablation of the SSV\(^6-8\). The main focus of improving therapy is currently aimed at reducing pain during and after treatment, as well as reducing heat-related trauma.

The recently introduced mechanochemical endovenous ablation (MOCA) technique using the ClariVein\textsuperscript{®} catheter (Vascular Insights LLC, Madison, CT, US) is unique: mechanical injury to the venous endothelium is combined with simultaneous catheter-guided infusion of a liquid sclerosant. No heat is generated and, therefore, tumescent is not required. Recent studies have proven that MOCA is a feasible and safe treatment for GSV insufficiency\(^9,10\).

We aimed to evaluate the initial results and the 1-year follow-up of MOCA using the ClariVein\textsuperscript{®} catheter in combination with polidocanol in SSV insufficiency.

Materials and methods

This study included all patients with symptomatic, primary SSV insufficiency treated in the St Antonius Hospital, Nieuwegein, and the Rijnstate Hospital, Arnhem, The Netherlands, from June 2010 to April 2011. Physical examination was performed by a vascular surgeon.
or a vascular physician assistant before treatment, and the CEAP classification and venous clinical severity score (VCSS) were assessed. All patients underwent duplex ultrasonography (DUS) of the deep and superficial veins of the affected leg. SSV insufficiency was defined as a retrograde flow >0.5 seconds after calf compression while standing.

Inclusion criteria were age >18 years, duplex-confirmed SSV incompetence at saphenopopliteal junction, long-segment SSV insufficiency (>10 cm), SSV diameter between 2.5 and 11 mm, C2-6 E A P R and written informed consent. Exclusion criteria were previous surgical treatment of the SSV, history of ipsilateral deep vein thrombosis (DVT), ipsilateral GSV or deep venous insufficiency, peripheral arterial occlusive disease or use of anticoagulants. Patients with allergy, pregnancy or lactation or other contraindications for the use of polidocanol were excluded. Ethical approval for research was granted.

Intervention
All interventions were performed with the ClariVein® device, combined with polidocanol (Aethoxysklerol®, Kreussler Pharma, Wiesbaden, Germany), by a vascular surgeon or a physician assistant on an outpatient basis. All physicians had previously performed >10 MOCA procedures using the ClariVein® in the GSV. No analgesia or antibiotics were administered before treatment.

The MOCA technique has been previously described.9 Briefly, the ClariVein® device is a disposable 2.6F single lumen catheter for infusing liquid sclerosant. A metal wire, fitted distally with a small ball, runs through the catheter (Figure 1). It is hypothesized that rotation of the wire (3000 rpm) induces intimal injury and disperses the liquid sclerosant. The entire length of the first 15 SSVs was treated with 1.5% polidocanol. In the later 35 cases, the proximal SSV (10-15 cm) was treated with 2 ml polidocanol (2%) and the remainder with polidocanol (1.5%). The protocol was altered because preliminary results in GSVs showed improved occlusion rates with the latter regimen. The total amount of used liquid sclerosant is noted in Table 1. In none of the patients the allowed daily dose of 2 mg/kg/day is exceeded. No concomitant phlebectomies were performed.

DUS was performed to confirm occlusion of treated vein. Patients wore compression stockings (30-40 mm Hg) continuously for the first 24 hour and during the daytime for the next 2 weeks. Patients were allowed to perform their daily activities immediately. No standard analgesics were prescribed.
Outcomes and follow-up protocol
The primary outcome measures were (1) technical success, defined as the ability to perform procedure as planned and achieve immediate occlusion after the procedure, and (2) anatomic success, defined as occlusion of treated vein. A recanalized SSV or treatment failure was defined as an open segment of >10 cm.

Secondary outcomes included complications, treatment time, patient satisfaction and procedural pain. The treatment time (from start of procedure to applying compression stocking) and length of the treated vein were noted. Patients were asked to record the level of pain during treatment on a visual analogue scale (VAS) from 0 cm (no pain) to 10 cm (worst imaginable pain). All patients were scheduled for a follow-up assessment at 6 weeks and 1 year by a vascular surgeon, including physical examination, determination of VCSS and DUS. After 6 weeks, patients were asked to quantify their satisfaction of the treatment in a 10-point score. In the case of residual varicosities, sclerotherapy was offered. Any postprocedural complications were noted. All data were gathered prospectively and stored in computerized database.

Statistical analysis
Variables are presented as mean with standard deviation (SD) or range for parametric continuous outcomes, as median with IQR for non-parametric continuous outcomes and as frequencies and percentages for categoric variables. Kaplan-Meier survival analysis was used to assess anatomic success rate. The log-rank test was used to compare anatomic
success between the initial protocol using 1.5% polidocanol and the latter protocol using the higher dosage. Change in VCSS was analyzed with the Wilcoxon signed rank test. Statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) 19.0 software (SPSS Inc, Chicago, IL, USA). A value of \( P < 0.05 \) was considered significant.

Results

The study included 50 consecutive patients who met the eligibility criteria. Patient characteristics are described in Table 1. At 1 year, three patients (6%) were lost to follow-up: one was free of complaints and refused follow-up, and the other two did not respond to repeated invitations for the follow-up assessment.

Occlusion rates

The technical success rate was 100%: all treated SSVs were occluded on DUS directly after MOCA. At 6 weeks, all treated veins (50 of 50) remained occluded. In 9 patients (18%) residual varicosities were treated by sclerotherapy to optimize cosmetic outcome. At 1 year, 44 of 47 SSVs were occluded, for an anatomic success of 94% (95% confidence interval (CI), 0.87-1). Patients who were lost to follow-up were censored at 6 weeks after treatment. At the 1-year follow-up, recanalization occurred in 2 of the 15 patients treated with low dose polidocanol (anatomic success, 87%; 95%CI, 0.71-1) and in 1 of 32 patients who received the elevated dose of polidocanol (anatomic success, 97%; 95%CI, 0.91-1). The difference between these subgroups was not significant (\( P = 0.187 \)).

Pain, patient satisfaction and duration of treatment

The median VAS pain score during treatment was 2 cm (IQR 2-4 cm). The median duration of treatment was 20 min (IQR 15-24 min). After 6 weeks, median patient satisfaction of the treatment was 8 (IQR 8-9).

Venous clinical severity score

At the 6-week follow-up, median VCSS had decreased significantly from 3 (IQR 2-5) pre-MOCA to 1 (IQR 1-3; \( P < 0.001 \)). At 1 year after treatment, VCSS remained significantly decreased compared with preprocedural scores (1 (IQR 1-2), \( P < 0.001 \)).
Table 1. Patient demographics and treatment characteristics

<table>
<thead>
<tr>
<th>Patient demographics</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients(a)</td>
<td>50 (100%)</td>
</tr>
<tr>
<td>Bilateral SSV insufficiency</td>
<td>none</td>
</tr>
<tr>
<td>Age(b), years</td>
<td>53 (25-84)</td>
</tr>
<tr>
<td>Male(a)</td>
<td>18 (36%)</td>
</tr>
<tr>
<td>Female(a)</td>
<td>32 (64%)</td>
</tr>
<tr>
<td>Weight(c), kg</td>
<td>76 (48-135)</td>
</tr>
<tr>
<td>Dosage of polidocanol 1.5%(a)</td>
<td>15 (30%)</td>
</tr>
<tr>
<td>Dosage of polidocanol 2 ml 2%/1.5%(a)</td>
<td>35 (70%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CEAP classification</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>C2 Varicose veins(a)</td>
<td>26 (52%)</td>
</tr>
<tr>
<td>C3 Oedema(a)</td>
<td>14 (28%)</td>
</tr>
<tr>
<td>C4 Skin changes(a)</td>
<td>8 (16%)</td>
</tr>
<tr>
<td>C5 Healed ulcer(a)</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>C6 Active ulcer(a)</td>
<td>1 (2%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment characteristics</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>SSV diameter(c), mm</td>
<td>4.8 (3.5-7)</td>
</tr>
<tr>
<td>Length of treated SSV(c), cm</td>
<td>22 (18-35)</td>
</tr>
<tr>
<td>Total volume of polidocanol(d), mL</td>
<td>4.4 ± 1.1</td>
</tr>
<tr>
<td>Total dosage of polidocanol(d), mg</td>
<td>72 ± 19</td>
</tr>
<tr>
<td>Duration of treatment(c), minutes</td>
<td>20 (15-24)</td>
</tr>
</tbody>
</table>

\(a\) Number (percentage of total); \(b\) Mean value (range); \(c\) Median value (interquartile range); \(d\) Mean value (SD)

SSV = small saphenous vein

Complications

No major complications were observed. Importantly, there were no signs of any nerve injury, and no DVT, skin necrosis, infection or hyperpigmentation was recorded. Minor complications included localized ecchymosis (12%), induration around the access site (12%) and transient superficial thrombophlebitis of the treated vein (14%). Pain lasted longer than 1 week in 5 patients (10%), all caused by superficial thrombophlebitis. After 6 weeks and 1 year, no additional complications were seen.
Discussion

This study is the first describing results of MOCA in treating SSV insufficiency. Technical success was 100%, and after 6 weeks of follow-up, no recanalization was noticed. At the 1-year follow-up, anatomic success persisted in 44 of 47 patients (94%). An important observation was the difference in anatomic success between the initial group treated with 1.5% polidocanol and the later group treated with 2% polidocanol in the proximal section. Although this difference is not significant, probably because of the small number of patients, an elevated dosage of liquid sclerosant may be a key in optimizing occlusion rates in MOCA.

The treatment of superficial venous insufficiency has changed dramatically in the last decade. Ligation, with or without surgical stripping, of insufficient saphenous veins has mostly been replaced by thermal endovenous catheter therapies, due to their superior efficacy and less invasive character. Results of EVLA for SSV insufficiency have repeatedly been described, with short-term occlusion rates ranging from 91% to 100%. RFA in treatment of varicosity of the SSV has only been described in a small series, but shows excellent results.

Ultrasound-guided foam sclerotherapy (UGFS) is another widely used minimally invasive technique to ablate varicose veins. Success rates of UGFS in SSV are 82% after a mean follow-up of 11 months. Although liquid sclerotherapy is effective in treating reticular and spider veins, it should not be used to treat insufficiency of saphenous veins, due to inferior occlusion rates of 17%-60% at 1 year.

Two studies describing the safety and the initial results of MOCA were recently published. Elias et al. showed an occlusion rate in GSV of 96.7% after MOCA using sodium tetradecyl sulphate (Sotradeco®, AngioDynamics, Queensbury, NY, US) after average follow-up of 260 days. MOCA combining ClariVein® with polidocanol showed occlusion in 97% of treated GSV at 6 weeks after treatment, and partial recanalization was described in 10%. No major complications occurred, and minor complains were acceptable in amount and severity.

All modalities in the treatment of varicose veins have specific complications. Ecchymosis and postprocedural pain seem inherent to heat-based therapies. In GSV, MOCA is associated with significantly less postoperative pain compared with RFA. More importantly, in SSV treatment, the anatomic proximity of the sural nerve poses an additional risk. In published data, transient sural nerve injury caused by ELVA varies between 1.3% and
11%\textsuperscript{6,11,14,19}. In redo SSV surgery, the incidence of numbness 1 year after treatment is as high as 28%\textsuperscript{20}. In general, major complications, such as skin burns, DVT and pulmonary embolism after EVLA, seldom occur (<1%). Transient thrombophlebitis occurred in 14% of patients, comparable with foam sclerotherapy and RFA\textsuperscript{11}. MOCA of the SSV has been proven to be safe: no major complications, including no sural nerve injuries, occurred. MOCA eliminates the need for tumescent anesthesia, which can be desirable, because it is time-consuming and requires multiple injections.

Clinical results after endovenous ablation, in general, are excellent. In our study group, a significant decrease in VCSS was measured at 6 weeks and at 1 year of follow-up compared with preprocedural scores. Patient satisfaction was high.

One of the limitations of this study is that the maximum diameter of treated SSVs was 11 mm. The technical and clinical success of MOCA in larger-diameter varicose veins is still unknown. Pain scores during MOCA were very low. Postprocedural pain scores were not measured. Further controlled studies are required to compare pain with other techniques in SSV ablation. Patients on oral anticoagulants were excluded; thus, we cannot provide data on the effect of anticoagulant therapy on MOCA. In contrast to endothermal therapy, anticoagulants might influence clot formation and lead to increased recanalization.

**Conclusion**

MOCA using the ClariVein\textsuperscript{®} device and polidocanol appears to be a safe, feasible and efficacious technique in the treatment of SSV insufficiency. Early and 1-year follow-up results are promising, with a 94% occlusion rate, no major complications and low pain scores.
References


